ERBB2 and neoplasm: Clinical management primarily depends on tumor stage, molecular features—such as human epidermal growth factor receptor 2 (HER2), programmed cell death ligand 1 (PD-L1), and MSI status—along with patient factors like performance status, age, medical history, and prior treatments.